NOVN CH0012005267

Report

Delayed Swiss Exchange - 07/23 11:30:30 am
84.57	CHF		+0.89%

07/23	NOVARTIS AG : Buy rating from UBS	MD
07/22	GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
07/22	GLAXOSMITHKLINE : GSK appoints consumer head as CEO of new spin-off	RE

News

Press Releases

Official Publications

Sector news

MarketScreener Strategies

Communiqués de presse de la société NOVARTIS AG

07/22	NOVARTIS : ESG Update - July 22, 2021	PU
07/21	NOVARTIS : Yes ☐ No ☒ (Form 6-K)	PU
07/21	NOVARTIS : Q2 Earnings Snapshot	AQ
07/21	NOVARTIS : Download the interactive presentation (PDF 4.5 MB)	PU
07/21	NOVARTIS : Q2 2021 results Media release English	PU
07/20	NOVARTIS : pledges 10-year commitment with Morehouse School of Medicine, 26 Hist..	PU
07/16	AUROBINDO PHARMA : Receives FDA Approval for Baclofen Tablets USP, 10 mg and 20 ..	AQ
07/14	NOVARTIS : announces NEJM publication of positive Phase III REACH3 data for Jaka..	PU
07/02	FEDERAL COURT DISMISSES ROCHE'S PMNO : Pirfenidone	AQ
06/28	NOVARTIS : International AG Novartis Global Communications CH-4002 Basel Switzer..	PU
06/23	NOVARTIS : Positive survival data for Novartis investigational radioligand thera..	PU
06/23	NOVARTIS : Kesimpta data show long-term preservation of IgG/IgM levels and no in..	AQ
06/23	NOVARTIS : and Hewlett Packard Enterprise join forces to advance Novartis global..	PU
06/22	NOVARTIS : Kesimpta® (ofatumumab) data show long-term preservation of IgG/IgM le..	PU
06/14	NOVARTIS : investigational oral therapy iptacopan (LNP023) shows benefit as mono..	AQ
06/07	NOVARTIS : announces new interim analysis Phase II data for iptacopan in rare ki..	PU
06/03	NOVARTIS : Kymriah pivotal trial demonstrates strong response rates and a remark..	AQ
05/27	ETON PHARMACEUTICALS : Particularity In Petitions Produces Positive Post-Grant R..	AQ
05/18	NOVARTIS : Sandoz announces plans to further strengthen its antibiotics manufact..	AQ
05/18	NOVARTIS : reaches milestone delivery of 1 billion courses of antimalarial treat..	PU
05/03	NOVARTIS : Sandoz confirms late-stage clinical development plans for proposed bi..	AQ
04/28	NOVARTIS : ESG Update - April 28, 2021 (PDF 0.3 MB)	PU
04/27	NOVARTIS : Q1 Earnings Snapshot	AQ
04/27	NOVARTIS : Q1 2021 Results Investor presentation	PU
04/27	NOVARTIS : Interim financial report (PDF 0.4 MB)	PU
04/23	NOVARTIS : to initiate SMART Phase 3b global study of Zolgensma in children up t..	PU
04/19	NOVARTIS : Kesimpta (ofatumumab) data at AAN showed reduction in disability prog..	AQ
04/16	NOVARTIS : Kesimpta® (ofatumumab) data at AAN showed reduction in disability pro..	PU
04/15	NOVARTIS : signs initial agreement to reserve capacity and implement the technol..	PU
04/13	ERASMUS UNIVERSITY ROTTERDAM : A bifurcated approach to labour market integratio..	AQ
03/31	NOVARTIS : expands targeted radioligand therapy pipeline with in-license for com..	AQ
03/31	GENMAB A/S : Announces European Marketing Authorization for Kesimpta in Relapsin..	AQ
03/30	NOVARTIS : receives EU approval for Kesimpta® (ofatumumab), the first and only s..	PU
03/24	Liquidia Corporation Reports Full-Year 2020 Financial Results and Provides Co..	AQ
03/24	NOVARTIS : statement on comment in Swiss media	PU
03/23	NOVARTIS INDIA : inaugurates innovative watershed project in India to increase w..	AQ
03/18	NOVARTIS : awards $450,000 to eight nonprofit organizations through the STEP Pro..	AQ
03/10	NOVARTIS : provides update on Phase III study evaluating canakinumab as second o..	AQ
03/08	NOVARTIS : Challenging a young scientist to focus on patients	AQ
03/04	NOVARTIS : signs initial agreement with CureVac to manufacture COVID-19 vaccine ..	PU
03/03	NOVARTIS AG : - Novartis shareholders approve all resolutions proposed by the Bo..	AQ
03/01	BEIGENE : Announces Closing of Collaboration with Novartis to Develop and Commer..	AQ
03/01	NOVARTIS : Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in..	AQ
03/01	BEIGENE : Novartis strengthens Oncology pipeline with successful closing of tisl..	AQ
02/26	NOVARTIS : strengthens Oncology pipeline with successful closing of tislelizumab..	PU
02/26	NOVARTIS : Federal Court Holds Section 8.2 Of The PMNOC Regulations Does Not Imp..	AQ
02/26	NOVARTIS : Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data i..	PU
02/19	NOVARTIS : Gates Foundation to fund Novartis' development of a sickle cell disea..	AQ
02/18	NOVARTIS : and the Bill and Melinda Gates Foundation collaborate to discover and..	AQ
02/17	NOVARTIS : data show multiple sclerosis patients and nurses prefer Kesimpta Sens..	AQ
02/17	NOVARTIS : Entresto granted expanded indication in chronic heart failure by FDA	AQ
02/16	NOVARTIS : data show multiple sclerosis patients and nurses prefer Kesimpta® (of..	PU
02/11	NOVARTIS : Sandoz announces agreement to acquire GSK's cephalosporin antibiotics..	AQ
02/09	NOVARTIS : receives FDA Breakthrough Therapy designations for investigational ST..	AQ
02/08	NOVARTIS : receives FDA Breakthrough Therapy designations for investigational ST..	PU
02/02	NOVARTIS : Federal Court Upholds Validity Of Two Patents Pertaining To ELIQUIS	AQ
02/01	NOVARTIS : renews WHO medicine donation pledge with aim of ending leprosy	AQ
02/01	GENMAB A/S : - CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing..	AQ
02/01	BIONTECH : Novartis signs initial agreement to provide manufacturing capacity fo..	AQ
01/29	NOVARTIS : signs initial agreement to provide manufacturing capacity for Pfizer-..	PU
01/29	NOVARTIS : renews WHO medicine donation pledge with aim of ending leprosy	PU
01/26	NOVARTIS : 4Q Earnings Snapshot	AQ
01/26	NOVARTIS : Annual Review 2020	PU
01/26	NOVARTIS : Access our interactive slide deck (PDF 12 MB)	PU
01/26	NOVARTIS : Download the investor presentation	PU
01/19	NOVARTIS : GSK and Novartis announce collaboration to support scientific researc..	AQ
01/19	NOVARTIS : and GSK announce collaboration to support scientific research into ge..	PU
01/14	NOVARTIS : Court Rejects Attempt To "Stretch" Patent Claim Language	AQ
01/14	NOVARTIS : ligelizumab (QGE031) receives FDA Breakthrough Therapy designation fo..	PU
01/13	NOVARTIS : Prosecution History Cannot Be Invoked Against Patent Licensees	AQ
01/11	NOVARTIS : Federal Court Clarifies Admissibility Of Prosecution History Evidence..	AQ
2020	NOVARTIS : Strict 45-Day Time Limit For Starting PMNOC Action Was Suspended By C..	AQ
2020	NOVARTIS : investigational oral therapy iptacopan receives FDA Breakthrough Ther..	AQ
2020	NOVARTIS : builds on commitment to addressing need in neuropsychiatric disorders..	PU
2020	NOVARTIS : reports positive topline results from second Phase III trial of Beovu..	AQ

1 2 3 4 5 6 7 8 9 10 Next

Analysis

Novartis : profit tops expectations as pandemic impact ebbs